Shares of biotech giant Biogen were falling on Wednesday after the company said it would delay the submitting of its Alzheimer’s treatment, aducanumab, for Food and Drug Administration approval. The company said it expects to finish submission for aducanumab by the end of the third quarter now. This will likely delay and put an FDA … Continue reading “Biogen Tumbles After Delay of Alzheimer’s Treatment Submission”
Tag: biib
Hot Stocks
Canaccord Analyst Gives “Buy” Rating on Biogen Despite Skepticism on Its Alzheimer’s Drug Getting Approved
Cannacord Genuity analyst Sumant Kulkarni has upgraded shares of Biogen Inc. from "hold" to "buy"…
January 28, 2020
Hot Stocks
Biogen Shares Explode on Positive Results from Alzheimer’s Drug Trial
Shares of Biogen were climbing higher on Friday after the company and Eisai announced the…
July 6, 2018
Biotech & Pharma
Biogen (BIIB) Gets Upgrade Because Of This Blockbuster Drug
Biogen shares were upgraded from hold to buy by Citi Research on Tuesday. The firm…
February 7, 2017
Biogen (BIIB) Shares Explode After WallStreet Report
A report by the Wall Street Journal, indicating that Merck & Co. and Allergan Plc…
August 2, 2016